Search Results - "Italiano, A."

Toxicity profiles of immunotherapy by Cousin, S, Seneschal, J, Italiano, A

“…Immunotherapies are changing the landscape of advanced solid tumor treatment. These therapies have different mechanisms of action and include oncolytic…”
Get full text

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group by Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J.D., Montagut, C., Normanno, N., Pantel, K., Pentheroudakis, G., Popat, S., Reis-Filho, J.S., Tie, J., Seoane, J., Tarazona, N., Yoshino, T., Turner, N.C.

“…Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a strong evidence base for use in patients with cancer. The European Society…”
Get full text

Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO) by Valentin, T, Le Cesne, A, Ray-Coquard, I, Italiano, A, Decanter, G, Bompas, E, Isambert, N, Thariat, J, Linassier, C, Bertucci, F, Bay, J.O, Bellesoeur, A, Penel, N, Le Guellec, S, Filleron, T, Chevreau, C

“…Abstract Background Malignant peripheral nerve sheath tumors (MPNST) are a rare subtype of soft tissue sarcoma. They can arise in irradiated fields, in…”
Get full text

Role of perioperative chemotherapy in soft-tissue sarcomas: It's time to end a never-ending story by Italiano, A., Stoeckle, E.

Get full text

Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS) by Casali, P.G., Le Cesne, A., Velasco, A.P., Kotasek, D., Rutkowski, P., Hohenberger, P., Fumagalli, E., Judson, I.R., Italiano, A., Gelderblom, H., Penel, N., Hartmann, J.T., Duffaud, F., Goldstein, D., Martin-Broto, J., Gronchi, A., Wardelmann, E., Marréaud, S., Zalcberg, J.R., Litière, S., Blay, J.-Y.

“…In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery in localized, high/intermediate-risk…”
Get full text

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort by Italiano, A., Bessede, A., Pulido, M., Bompas, E., Piperno-Neumann, S., Chevreau, C., Penel, N., Bertucci, F., Toulmonde, M., Bellera, C., Guegan, J. P., Rey, C., Sautès-Fridman, C., Bougoüin, A., Cantarel, C., Kind, M., Spalato, M., Dadone-Montaudie, B., Le Loarer, F., Blay, J. Y., Fridman, W. H.

“…Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that…”
Get full text

Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab by Cousin, S., Toulmonde, M., Kind, M., Cazeau, A.-L., Bechade, D., Coindre, J.-M., Italiano, A.

Get full text

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study by Le Cesne, A., Marec-Berard, P., Blay, J.-Y., Gaspar, N., Bertucci, F., Penel, N., Bompas, E., Cousin, S., Toulmonde, M., Bessede, A., Fridman, W.H., Sautes-Fridman, C., Kind, M., Le Loarer, F., Pulido, M., Italiano, A.

“…There are some lines of evidence suggesting a potential role of immunotherapy for treating patients with osteosarcomas. This was an open-label, multicentre,…”
Get full text

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages by Gomez-Roca, C.A., Italiano, A., Le Tourneau, C., Cassier, P.A., Toulmonde, M., D’Angelo, S.P., Campone, M., Weber, K.L., Loirat, D., Cannarile, M.A., Jegg, A.-M., Ries, C., Christen, R., Meneses-Lorente, G., Jacob, W., Klaman, I., Ooi, C.-H., Watson, C., Wonde, K., Reis, B., Michielin, F., Rüttinger, D., Delord, J.-P., Blay, J.-Y.

“…Emactuzumab is a monoclonal antibody against the colony-stimulating factor-1 receptor and targets tumor-associated macrophages (TAMs). This study assessed the…”
Get full text

Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer by Brunet, M., Crombé, A., Cousin, S., Vanhersecke, L., Le Loarer, F., Bessede, A., Italiano, A.

Get full text

Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment by Teyssonneau, D., Cousin, S., Italiano, A.

Get full text

Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group by Toulmonde, M., Bonvalot, S., Méeus, P., Stoeckle, E., Riou, O., Isambert, N., Bompas, E., Jafari, M., Delcambre-Lair, C., Saada, E., Le Cesne, A., Le Péchoux, C., Blay, J.Y., Piperno-Neumann, S., Chevreau, C., Bay, J.O., Brouste, V., Terrier, P., Ranchère-Vince, D., Neuville, A., Italiano, A.

“…Retroperitoneal sarcomas (RPS) are heterogeneous. No previous study has investigated the impact of specialized surgery, evaluated locoregional relapse (LRR),…”
Get full text

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance by Loriot, Y., Marabelle, A., Guégan, J.P., Danlos, F.X., Besse, B., Chaput, N., Massard, C., Planchard, D., Robert, C., Even, C., Khettab, M., Tselikas, L., Friboulet, L., André, F., Nafia, I., Le Loarer, F., Soria, J.C., Bessede, A., Italiano, A.

“…Immune checkpoint blockers (ICBs) are now widely used in oncology. Most patients, however, do not derive benefit from these agents. Therefore, there is a…”
Get full text

Pulmonary sarcoidosis or post-immunotherapy granulomatous reaction induced by the anti-PD-1 monoclonal antibody pembrolizumab: the terminology is not the key point by Cousin, S., Italiano, A.

“…In response to the letter to the editor titled: Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy…”
Get full text

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients by Bessede, A., Marabelle, A., Guégan, J.P., Danlos, F.X., Cousin, S., Peyraud, F., Chaput, N., Spalato, M., Roubaud, G., Cabart, M., Khettab, M., Chaibi, A., Rey, C., Nafia, I., Mahon, F.X., Soria, J.C., Italiano, A.

“…Acetaminophen (APAP) use has been associated with blunted vaccine immune responses. This study aimed to assess APAP impact on immunotherapy efficacy in…”
Get full text

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors by Peyraud, F., Guégan, J.-P., Bodet, D., Nafia, I., Fontan, L., Auzanneau, C., Cousin, S., Roubaud, G., Cabart, M., Chomy, F., Le Loarer, F., Chaput, N., Danlos, F.-X., Planchard, D., Even, C., Khettab, M., Tselikas, L., Besse, B., Barlesi, F., Soria, J.-C., Marabelle, A., Bessede, A., Italiano, A.

“…The discovery of immune checkpoint inhibitors (ICIs) has revolutionized the systemic approach to cancer treatment. Most patients receiving ICIs, however, do…”
Get full text

Advanced chondrosarcomas: role of chemotherapy and survival by Italiano, A., Mir, O., Cioffi, A., Palmerini, E., Piperno-Neumann, S., Perrin, C., Chaigneau, L., Penel, N., Duffaud, F., Kurtz, J.E., Collard, O., Bertucci, F., Bompas, E., Le Cesne, A., Maki, R.G., Ray Coquard, I., Blay, J.Y.

“…There are limited data about the role of chemotherapy in patients with advanced chondrosarcomas. The medical charts of 180 patients with advanced…”
Get full text

Ancient bronze coins from Mediterranean basin: LAMQS potentiality for lead isotopes comparative analysis with former mineral by Torrisi, L., Italiano, A., Torrisi, A.

“…[Display omitted] •Surface and bulk compositional elements in ancient bronze coins were investigated using XRF analysis.•Lead stable isotope 204Pb, 206Pb,…”
Get full text

Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA by Grellety, T., Peyraud, F., Sevenet, N., Tredan, O., Dohollou, N., Barouk-Simonet, E., Kind, M., Longy, M., Blay, J.-Y., Italiano, A.

Get full text

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM) by Bayle, A., Peyraud, F., Belcaid, L., Brunet, M., Aldea, M., Clodion, R., Dubos, P., Vasseur, D., Nicotra, C., Geraud, A., Sakkal, M., Cerbone, L., Blanc-Durand, F., Mosele, F., Martin Romano, P., Ngo Camus, M., Soubeyran, I., Khalifa, E., Alame, M., Blouin, L., Dinart, D., Bellera, C., Hollebecque, A., Ponce, S., Loriot, Y., Besse, B., Lacroix, L., Rouleau, E., Barlesi, F., Andre, F., Italiano, A.

Get full text